Industry News
115 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Merck Releases Interim Results for its Lung Cancer Immunotherapy

Merck Releases Interim Results for its Lung Cancer Immunotherapy | Industry News | Scoop.it
Preliminary results of Merck’s early-stage study evaluating its investigational lung cancer immunotherapy showed to trigger a response in roughly a quarter of participants.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA approves Genentech's Perjeta for early-stage breast cancer | Drug Store News

more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA Approves Neoadjuvant Pertuzumab Regimen

FDA Approves Neoadjuvant Pertuzumab Regimen | Industry News | Scoop.it
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA Approves New Dosing Option for CSL Behring's Hizentra

FDA Approves New Dosing Option for CSL Behring's Hizentra | Industry News | Scoop.it
CSL Behring announced that the US Food and Drug Administration (FDA) has approved a new dosing option for Hizentra in patients with primary immunodeficiency (PI).
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Bristol-Myers Squibb's Yervoy Demonstrates Positive Results in Long-Term Survival Study

Bristol-Myers Squibb's Yervoy Demonstrates Positive Results in Long-Term Survival Study | Industry News | Scoop.it
Bristol-Myers Squibb Company recently announced results from a pooled analysis of survival data from 12 studies evaluating Yervoy (ipilimumab) in patients with metastatic or locally advanced or unresectable melanoma.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

The Evolving Specialty Market

The Evolving Specialty Market | Industry News | Scoop.it
Health care reform will undoubtedly change the way specialty drugs are managed within the distribution supply chain, and specialty pharmacy providers may soon be competing with hospitals for patient share.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Prima's Ovarian Cancer Candidate Shows No Difference in Study

Prima's Ovarian Cancer Candidate Shows No Difference in Study | Industry News | Scoop.it
Prima BioMed Ltd recently announced top-line analysis of its mid-stage study evaluating its investigational ovarian cancer treatment.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

OncoMed Initiates Trial for its Anti-Cancer Stem Cell Candidate

OncoMed Initiates Trial for its Anti-Cancer Stem Cell Candidate | Industry News | Scoop.it
Today, OncoMed Pharmaceuticals, Inc. announced that it has initiated a Phase Ib/II trial for its anti-cancer stem cell candidate for treatment of ovarian cancer.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Sanofi Withdraws its Application for FDA Approval of Lixisenatide

Sanofi Withdraws its Application for FDA Approval of Lixisenatide | Industry News | Scoop.it
Today, Sanofi announced that it temporarily withdrew the New Drug Application (NDA) for its experimental type 2 diabetes drug.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Viralytics Melanoma Treatment Meets Primary Endpoint in Phase II Trial

Viralytics Melanoma Treatment Meets Primary Endpoint in Phase II Trial | Industry News | Scoop.it
Viralytics Limited recently announced that its investigational melanoma trial achieved its primary endpoint for treatment of patients with late-stage melanoma.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA Reviewers Back Perjeta for Early Stage Treatment of Breast Cancer

FDA Reviewers Back Perjeta for Early Stage Treatment of Breast Cancer | Industry News | Scoop.it
The US Food and Drug Administration (FDA) issued a positive report ahead of the review of Genentech’s breast cancer drug Perjeta (pertuzumab).
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Novartis' Candidate Shows Superiority to Enbrel for Patients with Psoriasis

Novartis' Candidate Shows Superiority to Enbrel for Patients with Psoriasis | Industry News | Scoop.it
Today, Novartis announced positive results from its late-stage study evaluating its psoriasis candidate versus Enbrel (etanercept).
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA Warns of Serious Brain Infection in Patient Taking Novartis' Gilenya

FDA Warns of Serious Brain Infection in Patient Taking Novartis' Gilenya | Industry News | Scoop.it
Today, the US Food and Drug Administration (FDA) released a safety alert informing the public that a patient in Europe who was taking Gilenya (fingolimod) for treatment of multiple sclerosis (MS) developed a rare and serious brain infection.
more...
CedimCat's curator insight, October 1, 2013 9:47 AM

 rare and serious brain infection

Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Researchers Identify Antidepressants that Have Potential for Treating Small Cell Lung Cancer

Researchers Identify Antidepressants that Have Potential for Treating Small Cell Lung Cancer | Industry News | Scoop.it
According to a new study, a class of antidepressants has been identified as a potential new treatment for small cell lung cancer (SCLC).
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA approves UCB's Cimzia for psoriatic arthritis | Drug Store News

more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Soft Tissue Lesions Predict Shorter Survival Than Bone Lesions in Relapsed Multiple Myeloma

Soft Tissue Lesions Predict Shorter Survival Than Bone Lesions in Relapsed Multiple Myeloma | Industry News | Scoop.it
Investigators in the Czech Republic have found an association between soft tissue lesions and diminished survival in patients with multiple myeloma.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Eli Lilly's Breast Cancer Candidate Fails in Late Stage Study

Eli Lilly's Breast Cancer Candidate Fails in Late Stage Study | Industry News | Scoop.it
Today, Eli Lilly and Company announced that its late-stage study of its breast cancer drug failed to meet its primary endpoint of progression-free survival (PFS).
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Kadcyla Shows Significant Improvement in Progression Free Survival in Patients with Advanced Breast Cancer

Kadcyla Shows Significant Improvement in Progression Free Survival in Patients with Advanced Breast Cancer | Industry News | Scoop.it
Roche’s Genentech recently announced that Kadcyla (ado-trastuzumab emtansine) nearly doubled the time that people lived without their disease worsening compared to treatment of physician’s choice.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Are Patients Taking Oral Cancer Regimens as Prescribed?

Are Patients Taking Oral Cancer Regimens as Prescribed? | Industry News | Scoop.it
Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Ablynx Signs Deal with AbbVie for its Rheumatoid Arthritis Candidate

Ablynx Signs Deal with AbbVie for its Rheumatoid Arthritis Candidate | Industry News | Scoop.it
Ablynx and AbbVie recently announced that they have entered into a global license agreement for the development and commercialization of a treatment for patients with rheumatoid arthritis.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Early Disease-Modifying Drug Therapy Delays Multiple Sclerosis Progression

Early Disease-Modifying Drug Therapy Delays Multiple Sclerosis Progression | Industry News | Scoop.it
A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

FDA approves J&J's Stelara for psoriatic arthritis | Drug Store News

more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

AstraZeneca Buys Rights to Merck's Cancer Drug

AstraZeneca Buys Rights to Merck's Cancer Drug | Industry News | Scoop.it
Merck & Co Inc. has licensed its experimental mid-stage cancer drug to AstraZeneca for an upfront fee of $50 million.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Roche Partners with Inovio for Cancer and Hepatitis B Immunotherapies

Roche Partners with Inovio for Cancer and Hepatitis B Immunotherapies | Industry News | Scoop.it
Roche and Inovio Pharmaceuticals, Inc. announced that they have entered into an exclusive worldwide license agreement for immunotherapies for prostate cancer and hepatitis B.
more...
No comment yet.
Scooped by BioPlus Specialty Pharmacy
Scoop.it!

Oncolytics Announces Positive Data from its Squamous Cell Lung Cancer Study

Oncolytics Announces Positive Data from its Squamous Cell Lung Cancer Study | Industry News | Scoop.it
Today, Oncolytics Biotech Inc. announced positive results from its mid-stage trial evaluating its lung cancer candidate.
more...
No comment yet.